Researchers had thought 2-HOBA might reduce the risk of AFib recurrence after catheter ablation procedures. What they found, however, was that treatment with the compound was actually harmful for patients instead of helpful. 

Catecholaminergic polymorphic ventricular tachycardia is a rare, potentially fatal heart rhythm disorder. A new gene therapy candidate from Solid Biosciences is now one step closer to FDA approval. 

Targeting high-risk patients with single-pill combination therapies, also known as polypills, could change healthcare on a global scale, according new data published in the Journal of the American College of Cardiology. 

The company's automated insulin pump can now be used to treat more patients thanks to an expanded CE mark approval. Could updates from the FDA be next?

Are care teams doing enough to take on inflammation? The American Heart Association hopes this new research initiative can help answer that question, and many others. 

The ongoing debate continues. The team behind this latest analysis pointed to more than 40 years of research to make its point.

Finerenone, sold by Bayer under the brand name Kerendia, is now approved in the United States for the treatment of HFmrEF and HFpEF. The drug has already been used for years to treat patients with chronic kidney disease and type 2 diabetes.

Statins appear to be the most impactful for patients diagnosed with hypertension or cerebrovascular disease.